Cargando…

Females present higher dose‐adjusted drug concentrations of metoprolol and allopurinol/oxypurinol than males

Females present a higher risk of adverse drug reactions. Sex‐related differences in drug concentrations may contribute to these observations but they remain understudied given the underrepresentation of females in clinical trials. The aim of this study was to investigate whether anthropometric and s...

Descripción completa

Detalles Bibliográficos
Autores principales: Hindi, Jessica, Pilon, Marc‐Olivier, Meloche, Maxime, Leclair, Grégoire, Oussaïd, Essaïd, St‐Jean, Isabelle, Jutras, Martin, Gaulin, Marie‐Josée, Mongrain, Ian, Busseuil, David, Rouleau, Jean Lucien, Tardif, Jean‐Claude, Dubé, Marie‐Pierre, de Denus, Simon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10175982/
https://www.ncbi.nlm.nih.gov/pubmed/36864560
http://dx.doi.org/10.1111/cts.13497
_version_ 1785040334906982400
author Hindi, Jessica
Pilon, Marc‐Olivier
Meloche, Maxime
Leclair, Grégoire
Oussaïd, Essaïd
St‐Jean, Isabelle
Jutras, Martin
Gaulin, Marie‐Josée
Mongrain, Ian
Busseuil, David
Rouleau, Jean Lucien
Tardif, Jean‐Claude
Dubé, Marie‐Pierre
de Denus, Simon
author_facet Hindi, Jessica
Pilon, Marc‐Olivier
Meloche, Maxime
Leclair, Grégoire
Oussaïd, Essaïd
St‐Jean, Isabelle
Jutras, Martin
Gaulin, Marie‐Josée
Mongrain, Ian
Busseuil, David
Rouleau, Jean Lucien
Tardif, Jean‐Claude
Dubé, Marie‐Pierre
de Denus, Simon
author_sort Hindi, Jessica
collection PubMed
description Females present a higher risk of adverse drug reactions. Sex‐related differences in drug concentrations may contribute to these observations but they remain understudied given the underrepresentation of females in clinical trials. The aim of this study was to investigate whether anthropometric and socioeconomic factors and comorbidities could explain sex‐related differences in concentrations and dosing for metoprolol and oxypurinol, the active metabolite of allopurinol. We conducted an analysis of two cross‐sectional studies. Participants were self‐described “White” adults taking metoprolol or allopurinol selected from the Montreal Heart Institute Hospital Cohort. A total of 1007 participants were included in the metoprolol subpopulation and 459 participants in the allopurinol subpopulation; 73% and 86% of the participants from the metoprolol and allopurinol subpopulations were males, respectively. Females presented higher age‐ and dose‐adjusted concentrations of both metoprolol and oxypurinol (both p < 0.03). Accordingly, females presented higher unadjusted and age‐adjusted concentration:dose ratio of both metoprolol and allopurinol/oxypurinol compared to males (all p < 3.0 × 10(−4)). Sex remained an independent predictor of metoprolol concentrations (p < 0.01), but not of oxypurinol concentrations, after adjusting for other predictors. In addition to sex, age, daily dose, use of moderate to strong CYP2D6 inhibitors, weight, and CYP2D6 genotype‐inferred phenotype were associated with concentrations of metoprolol (all p < 0.01). Daily dose, weight, estimated glomerular filtration rate (eGFR), and employment status were associated with oxypurinol concentrations (all p < 0.01). Females present higher dose‐adjusted concentrations of metoprolol and oxypurinol than males. This suggests the need for sex‐specific dosing requirements for these drugs, although this hypothesis should be validated in prospective studies.
format Online
Article
Text
id pubmed-10175982
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-101759822023-05-13 Females present higher dose‐adjusted drug concentrations of metoprolol and allopurinol/oxypurinol than males Hindi, Jessica Pilon, Marc‐Olivier Meloche, Maxime Leclair, Grégoire Oussaïd, Essaïd St‐Jean, Isabelle Jutras, Martin Gaulin, Marie‐Josée Mongrain, Ian Busseuil, David Rouleau, Jean Lucien Tardif, Jean‐Claude Dubé, Marie‐Pierre de Denus, Simon Clin Transl Sci Research Females present a higher risk of adverse drug reactions. Sex‐related differences in drug concentrations may contribute to these observations but they remain understudied given the underrepresentation of females in clinical trials. The aim of this study was to investigate whether anthropometric and socioeconomic factors and comorbidities could explain sex‐related differences in concentrations and dosing for metoprolol and oxypurinol, the active metabolite of allopurinol. We conducted an analysis of two cross‐sectional studies. Participants were self‐described “White” adults taking metoprolol or allopurinol selected from the Montreal Heart Institute Hospital Cohort. A total of 1007 participants were included in the metoprolol subpopulation and 459 participants in the allopurinol subpopulation; 73% and 86% of the participants from the metoprolol and allopurinol subpopulations were males, respectively. Females presented higher age‐ and dose‐adjusted concentrations of both metoprolol and oxypurinol (both p < 0.03). Accordingly, females presented higher unadjusted and age‐adjusted concentration:dose ratio of both metoprolol and allopurinol/oxypurinol compared to males (all p < 3.0 × 10(−4)). Sex remained an independent predictor of metoprolol concentrations (p < 0.01), but not of oxypurinol concentrations, after adjusting for other predictors. In addition to sex, age, daily dose, use of moderate to strong CYP2D6 inhibitors, weight, and CYP2D6 genotype‐inferred phenotype were associated with concentrations of metoprolol (all p < 0.01). Daily dose, weight, estimated glomerular filtration rate (eGFR), and employment status were associated with oxypurinol concentrations (all p < 0.01). Females present higher dose‐adjusted concentrations of metoprolol and oxypurinol than males. This suggests the need for sex‐specific dosing requirements for these drugs, although this hypothesis should be validated in prospective studies. John Wiley and Sons Inc. 2023-03-02 /pmc/articles/PMC10175982/ /pubmed/36864560 http://dx.doi.org/10.1111/cts.13497 Text en © 2023 The Authors. Clinical and Translational Science published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Research
Hindi, Jessica
Pilon, Marc‐Olivier
Meloche, Maxime
Leclair, Grégoire
Oussaïd, Essaïd
St‐Jean, Isabelle
Jutras, Martin
Gaulin, Marie‐Josée
Mongrain, Ian
Busseuil, David
Rouleau, Jean Lucien
Tardif, Jean‐Claude
Dubé, Marie‐Pierre
de Denus, Simon
Females present higher dose‐adjusted drug concentrations of metoprolol and allopurinol/oxypurinol than males
title Females present higher dose‐adjusted drug concentrations of metoprolol and allopurinol/oxypurinol than males
title_full Females present higher dose‐adjusted drug concentrations of metoprolol and allopurinol/oxypurinol than males
title_fullStr Females present higher dose‐adjusted drug concentrations of metoprolol and allopurinol/oxypurinol than males
title_full_unstemmed Females present higher dose‐adjusted drug concentrations of metoprolol and allopurinol/oxypurinol than males
title_short Females present higher dose‐adjusted drug concentrations of metoprolol and allopurinol/oxypurinol than males
title_sort females present higher dose‐adjusted drug concentrations of metoprolol and allopurinol/oxypurinol than males
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10175982/
https://www.ncbi.nlm.nih.gov/pubmed/36864560
http://dx.doi.org/10.1111/cts.13497
work_keys_str_mv AT hindijessica femalespresenthigherdoseadjusteddrugconcentrationsofmetoprololandallopurinoloxypurinolthanmales
AT pilonmarcolivier femalespresenthigherdoseadjusteddrugconcentrationsofmetoprololandallopurinoloxypurinolthanmales
AT melochemaxime femalespresenthigherdoseadjusteddrugconcentrationsofmetoprololandallopurinoloxypurinolthanmales
AT leclairgregoire femalespresenthigherdoseadjusteddrugconcentrationsofmetoprololandallopurinoloxypurinolthanmales
AT oussaidessaid femalespresenthigherdoseadjusteddrugconcentrationsofmetoprololandallopurinoloxypurinolthanmales
AT stjeanisabelle femalespresenthigherdoseadjusteddrugconcentrationsofmetoprololandallopurinoloxypurinolthanmales
AT jutrasmartin femalespresenthigherdoseadjusteddrugconcentrationsofmetoprololandallopurinoloxypurinolthanmales
AT gaulinmariejosee femalespresenthigherdoseadjusteddrugconcentrationsofmetoprololandallopurinoloxypurinolthanmales
AT mongrainian femalespresenthigherdoseadjusteddrugconcentrationsofmetoprololandallopurinoloxypurinolthanmales
AT busseuildavid femalespresenthigherdoseadjusteddrugconcentrationsofmetoprololandallopurinoloxypurinolthanmales
AT rouleaujeanlucien femalespresenthigherdoseadjusteddrugconcentrationsofmetoprololandallopurinoloxypurinolthanmales
AT tardifjeanclaude femalespresenthigherdoseadjusteddrugconcentrationsofmetoprololandallopurinoloxypurinolthanmales
AT dubemariepierre femalespresenthigherdoseadjusteddrugconcentrationsofmetoprololandallopurinoloxypurinolthanmales
AT dedenussimon femalespresenthigherdoseadjusteddrugconcentrationsofmetoprololandallopurinoloxypurinolthanmales